🇺🇸 FDA
Pipeline program

NX-5948

NX-5948-201

Phase 2 small_molecule active

Quick answer

NX-5948 for Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) is a Phase 2 program (small_molecule) at Nurix Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Nurix Therapeutics
Indication
Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials